Hyperglycemia in Diabetes Drives Hepatic Fibrosis Through the Non-Enzymatic Function of HK2 and AGEs-mediated Matrix Stiffening. (PubMed, Int J Biol Sci) - Sep 30, 2026 - "Empagliflozin alleviated hepatic fibrosis progression through decreasing AGEs accumulation and suppressing STAT3 and FOXO1 phosphorylation in HSCs. From the new perspectives of the non-metabolic functions of metabolic enzymes and matrix biomechanics, this study sheds light on a new synergistic regulatory pathway through which diabetes promotes hepatic fibrosis and highlights empagliflozin as a potential therapeutic agent for diabetic hepatic fibrosis."
Journal • Diabetes • Fibrosis • Hepatology • Immunology • Metabolic Disorders • KLF4 • STAT3
|
|
Chuxin Huang; Hongmei Yu; Jiajun Li; Jiali Qian; Jie Chen; Jiefeng Cui; Jinya Huang; Li Zhang; Miao Li; Qiwen Zhou; Rui Liu; Xuanchun Wang; Yawen Zhang; Yehong Yang; Ying Liu; Yingying Zhao; Zihao Xu; Ziyu Ren
|